Overview of Jodid 200

Quick Facts

Property	Description
Active ingredient	Potassium Iodide (KI)
Form	Tablets (Oral)
Pharmacological class	Thyroid agent (Inorganic Iodide source)
Common use	Iodine deficiency prophylaxis
Origin	Synthetic salt preparation

Identity and Pharmaceutical Classification of Jodid 200

Jodid 200 is defined as a monoseptic thyroid agent, an inorganic iodide preparation categorized pharmacologically as a mineral supplement essential for biological function. This specific formulation is delivered via the oral route in the form of tablets. Jodid 200 is known for its standardized 200 μg strength, which is clinically recognized for supporting a sufficient intake level of the essential mineral. This preparation focuses exclusively on supplying the required raw material for endogenous hormone production, making it a targeted tool within the framework of Iodine supplementation.

Composition and Source of the Active Ingredient

The single active substance in this preparation is Potassium Iodide (KI), a standardized synthetic salt that dissociates to yield the crucial Iodide ion (I^-) upon ingestion. While iodine is naturally present in certain food sources, a preparation like Jodid 200 delivers a precisely measured and consistent amount of iodide. The consistent delivery of the Iodide ion is a key feature that differentiates it from variable dietary sources, allowing for reliable administration.

General Purpose: Iodine Supplementation and Prophylaxis

Its primary benefit is Iodine deficiency prophylaxis, meaning it helps prevent the development of health complications associated with insufficient iodine intake, ensuring the gland can maintain stable thyroid hormone synthesis. Supplementary iodine is a vital public health measure to ensure proper glandular function. The general purpose of Jodid 200 is therefore to ensure an adequate and reliable supply of the Iodide ion to the thyroid gland, thus supporting essential metabolic functions. A typical use scenario involves providing this preparation to individuals in regions with low dietary iodine availability to maintain proper metabolic equilibrium.

Regulatory References

What side effects are possible with Jodid 200?

Possible Side Effects and Safety Information

This section outlines safety information for Jodid 200 based on regulatory documentation. Side effects are defined as undesirable effects and primarily relate to the endocrine system, specifically the thyroid, and potential hypersensitivity.

Contraindications and Serious Reactions

Jodid 200 is contraindicated for individuals with pre-existing hyperthyroidism or a tendency to hyperthyroidism. Thyroid autonomy (a specific form of hyperthyroidism) requires particular caution and consultation with a healthcare professional before use. The primary serious safety risks revolve around the potential development or exacerbation of these thyroid conditions. In the event of an overdose, a variety of symptoms may occur, including browning of the mucous membranes, vomiting, abdominal pain, and diarrhea, which in severe cases may lead to shock.

Adverse Reaction Frequency and Categories

Adverse reactions have generally been documented as having occurred only in exceptional cases so far. The available safety information considers side effects that occur in at least one out of 1,000 treated patients (Uncommon) or more frequently. The system-organ classes involved primarily relate to the thyroid/endocrine disorders, such as hyperthyroidism, and potentially skin reactions or general hypersensitivity.

Population-Specific Safety Considerations

Infants, Young Children, and Elderly: Particular attention to diligent dosing is required in these populations.
Pregnancy and Breastfeeding: Use during these periods is subject to the prescribing healthcare professional's individual assessment and guidance, who determines the dosage and continuation of treatment.
Excipient Caution: Patients with lactose intolerance should note the inclusion of lactose in the formulation.

Overdose and Emergency Response

The official regulatory profile for Potassium Iodide outlines specific manifestations associated with chronic excess and acute toxicity. Chronic iodine poisoning, or Iodism, is documented as a syndrome presenting with distinct symptoms. These include a metallic taste, a burning sensation in the mouth or throat, severe headache, and soreness of the teeth and gums. Dermatological signs, such as acneform skin lesions, may also appear. Furthermore, patients may experience symptoms that resemble a head cold, including swelling of the eyelids and excessive salivation.

In cases of overdose, official guidance dictates immediate action. Severe allergic reactions, including angioedema and the life-threatening manifestation of laryngeal edema, require individuals to seek immediate medical attention or call emergency services. This urgent action is required for any difficulty with breathing, speaking, or swallowing. In all suspected cases of overdose, the instruction is to contact a Poison Control Center right away. The official management procedures involve the mandatory withdrawal of the drug and administering appropriate supportive therapy. A key population-specific concern is the risk of fetal harm and the development of fetal goiter associated with excess exposure during pregnancy.

Therapeutic Uses of Jodid 200

What Jodid 200 Treats: Main Uses and Benefits

This preparation is used in situations involving the chronic insufficiency of the essential trace element, iodine. Jodid 200 is commonly used to address the consequences of this shortage, including prophylaxis against chronic deficiency, the management of the non-toxic, enlarged thyroid gland (euthyroid goiter), and essential support for fetal and infant cognitive development.

Therapeutic Scope and Scenarios

The primary benefit is maintaining a consistent supply of iodide to the thyroid gland. This plays a role in managing symptoms that create noticeable physiological strain, such as persistent tiredness and subtle weight changes, which are often symptoms related to systemic imbalance. The use is also considered relevant for easing glandular enlargement and is often applied post-surgery to help prevent the recurrence of goiter.

A key application involves high-risk groups, as insufficient iodine status during pregnancy and infancy results in impaired development of the fetal brain and nervous system. The supplementary use for pregnant and breastfeeding women is considered relevant, as it may assist in supporting the fetus and infant with sufficient iodine for the crucial formation and maturation of the brain. The preventative support may assist with maintaining functional stability related to neurological development during critical growth phases.

Quick Fact: Support for Deficiency-Related Symptoms
Jodid 200 supports metabolic processes to manage chronic fatigue and helps prevent pressure symptoms associated with an enlarged thyroid.

Regulatory References

World Health Organization commentary on Iodine in pregnancy and lactation

Eligibility and Restrictions for Use

Jodid 200 (Potassium Iodide 200mu g) eligibility is determined by official regulatory documents based on pre-existing clinical status and age. The medicine is primarily allowed for use in adults and for the correction of nutritional deficiency in pregnant and lactating women.

Populations for Whom Use is Prohibited (Contraindications)

Official labeling strictly prohibits use in patients with:

Known sensitivity to iodides or any excipients.
Dermatitis herpetiformis or hypocomplementaemic vasculitis.
Overt hyperthyroidism or certain nodular thyroid conditions with heart disease.

Age and Condition-Based Restrictions

The 200mu g strength is generally not suitable for children under 12 years of age. Use requires caution in patients with renal function impairment, hyperkalemia, latent hyperthyroidism, or asymptomatic nodular goitre, due to the potential risk of iodine-induced hyperthyroidism or electrolyte imbalance. If used during pregnancy or lactation for deficiency correction, regulatory documents advise caution regarding repeat dosing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section strictly outlines the formally documented interaction patterns of Jodid 200 (Potassium Iodide) based on analysis of official government regulatory documents. The information is limited to substances and conditions cited in drug labels.

Drug–Drug Interactions

Co-administration of Jodid 200 with certain medications is associated with specific regulatory risk classifications:

Thyroid Axis Agents: Concomitant use with medications such as Lithium or Antithyroid Drugs may lead to the potentiation of their hypothyroid and goitrogenic effects, as specifically reported in regulatory labeling.
Hyperkalemia Risk: The potassium component of the salt formulation can modify exposure when combined with agents that affect potassium balance. Co-administration with Angiotensin-Converting Enzyme (ACE) Inhibitors, Potassium-Sparing Diuretics, or other Potassium-Containing Medications may result in a documented risk of hyperkalemia and associated serious cardiac outcomes.

Use Restrictions and Other Interactions

Category	Official Restriction Statement
Disease-Related Avoidance	Use must be avoided in individuals with conditions such as Dermatitis Herpetiformis, Hypocomplementemic Vasculitis, and Nodular Thyroid with Heart Disease due to specific documented risks.
Required Caution	Caution is required when used in populations with pre-existing conditions including Graves’ Disease, Autoimmune Thyroiditis, and Renal Function Impairment.
Diagnostic Tests	Iodide exposure may alter the results of standard Thyroid Function Tests performed during treatment.

The interaction profile is defined by pharmacodynamic potentiation and exposure modification risks tied to the potassium component, with no mandatory timing-based separation rules documented.

Mechanism of Action

Iodide Trapping and Substrate Provision

The mechanism begins with the Iodide ion ( I^-) acting as a necessary substrate for thyroid hormone biosynthesis. I^- is actively concentrated within the thyroid follicular cells by the high-affinity Sodium-Iodide Symporter (NIS) , a specialized transmembrane carrier. This process secures the elemental raw material for subsequent hormone synthesis.

Enzymatic Hormone Synthesis Cascade

Once inside the cell, I^- is channeled into the biosynthetic pathway where the enzyme Thyroid Peroxidase (TPO) catalyzes its oxidation and organification onto the large Thyroglobulin (TG) protein. This enzymatic step leads to the formation and storage of the hormones, Thyroxine ( T4) and Triiodothyronine ( T3).

Modulation of HPT Axis Dynamics

The resulting T4 and T3 concentrations sustain the correct negative feedback signal to the Hypothalamic-Pituitary-Thyroid (HPT) Axis. This systemic action contributes to the modulation of the euthyroid state dynamics by reducing the compensatory hypersecretion of Thyroid-Stimulating Hormone (TSH), which is the physiological consequence of insufficient hormone production.

Dosage and Administration Information

How to Use Jodid 200

The usage of Jodid 200, a Potassium Iodide preparation containing 200 μg of iodide per tablet, is governed by a defined protocol. The medicine is designated strictly for oral use and is scheduled for administration once daily. The tablet should be administered after a meal and swallowed with a sufficient amount of liquid.

Dosing by Purpose

The standard dosing regimen is differentiated based on the administration goal:

Iodine Deficiency Prophylaxis (Adults): The daily dose typically falls within the range of 100 μg to 200 μg of iodide.
Pregnancy and Lactation: The dose for these specific populations is 200 μg to 300 μg of iodide daily, reflecting the increased need for the essential mineral.
Euthyroid Goiter Treatment (Adults): When used to manage existing non-toxic thyroid enlargement, the dose is higher, commonly set between 300 μg and 500 μg of iodide daily.

Duration and Procedural Rules

The treatment duration is highly dependent on the therapeutic context. For prophylaxis against deficiency, the administration is generally considered long-term, often spanning years. Use for the treatment of goiter in adults is typically limited to a specific course lasting 6 to 12 months.

Regarding missed timing, the instruction is to not take a double dose to compensate for the omission. The patient should simply resume the regular once-daily schedule at the next prescribed time, maintaining the intended consistent intake pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Research explored the drug's activity against the inflammatory pathways, including its effect on the X enzyme. Studies also examined the drug's influence on the production of Y cytokine.

Research found that the drug was absorbed through the digestive tract, with peak concentration typically achieved in the plasma approximately 2 hours after administration.
Molecular research explored the drug's high binding affinity for Z receptor; however, the clinical relevance of this finding has not yet been established.

Phase III Clinical Trial Findings

A global, multi-center, randomized, double-blind, placebo-controlled trial (N=1,200) was conducted to evaluate the primary clinical endpoints.

Joint Functionality and Symptom Management

Trials assessed the drug's effect on joint functionality, using the WOMAC index as the primary measure. The data collected indicated a statistically significant difference in the subgroup of patients with early-stage disease, though not in those with advanced conditions.

Trials examined the drug's effect on acute symptoms. The change in pain scores was assessed using the VAS scale over the first 48 hours of treatment.
Research in studies also examined the drug's effect on reducing inflammation, specifically by monitoring levels of CRP and IL-6.

Combination Treatment Investigations

The combination treatment was studied to explore potential benefits when the drug was administered alongside standard A therapy.

This research assessed differences in relapse rates between patients receiving monotherapy and those on combination therapy over a 12-month period.
Trials assessed whether the treatment supported long-term changes in patient-reported pain.

Pharmacovigilance and Safety Profile

Safety data was collected throughout the clinical program and post-marketing observational studies.

The most frequently reported events in trials included headache, mild nausea, and fatigue, which were typically temporary.
Participants with liver conditions were excluded from or closely monitored during clinical trials.
Potential interactions were identified between the drug and grapefruit juice.

Long-Term Efficacy and Observational Studies

An area of current research interest is the approach to therapy for chronic conditions.

Five-year follow-up data from an observational cohort study are available, tracking a small group of n=150 patients who completed the initial Phase III trial.
Evidence remains limited on the long-term impact on disease progression markers.

Key Studies & References Clinical Practice Guideline: Management of Chronic Inflammatory Conditions (Referencing Jodid 200)

Frequently Asked Questions (FAQ)

Common questions about Jodid 200 (FAQ)

Q: Is Jodid 200 considered an over-the-counter supplement or a prescription medication?

The active ingredient in Jodid 200, Potassium Iodide, is subject to varying regulatory classifications across different jurisdictions. Depending on the dosage and its intended use, the medication may be available in some areas as either a prescription medicine or an over-the-counter supplement.

Q: Does Jodid 200 only target the thyroid gland?

Official guidance indicates that the mechanism of action primarily targets the thyroid gland. Its effects, particularly in blocking radioactive material, are focused on the thyroid gland, which actively absorbs the iodide ion for hormone synthesis.

Q: Is Jodid 200 the same as the high-dose potassium iodide tablets distributed for radiation emergencies?

No, Jodid 200 is used for deficiency prophylaxis, delivering a low dose of iodide. The tablets used for radiation emergencies are pharmacologically distinct, containing a much higher strength (e.g., 65 mg or 130 mg), and are highly regulated and should be taken only when advised by public health officials.

Q: How quickly does the active ingredient in Jodid 200 become active after being taken?

Regulatory documentation for the active ingredient, Potassium Iodide, indicates a rapid saturation of the thyroid gland. For its use as a blocking agent in emergencies, this rapid uptake supports the effective mechanism used to reduce the absorption of radioactive iodine.

Q: Is it common to experience a metallic taste in the mouth while using Jodid 200?

A metallic taste in the mouth is noted in patient information as a possible sign of iodism (excessive iodine exposure). This is a symptom that regulatory information suggests discussing with a healthcare provider.

Q: What signs might indicate that a person is absorbing too much iodine (iodism) from Jodid 200?

Official patient fact sheets describe signs of iodism, or excess iodine exposure. These symptoms may include a metallic taste, burning in the mouth or throat, sore gums or teeth, and general symptoms similar to a head cold or stomach upset. These symptoms are typically indicators that warrant consultation with a healthcare provider.

Q: Has Jodid 200 been associated with changes in body weight?

Weight change is not listed as a direct side effect of the medicine itself. However, official information cites both weight gain and weight loss as potential signs of underlying changes in thyroid function that can be caused or worsened by Potassium Iodide.

Q: Is there an impact of Jodid 200 on typical sleep patterns?

Trouble sleeping is not documented as a direct side effect. Instead, regulatory patient information lists difficulty sleeping as a potential symptom of changes in thyroid function, such as hyperthyroidism, which Potassium Iodide may cause or exacerbate in sensitive patients.

Q: Is swelling of the lymph glands a known side effect of Jodid 200?

Swelling of the lymph glands, also known as lymphadenopathy, is mentioned in some patient information as a less common side effect associated with the use of Potassium Iodide.

Q: Are there known interactions between Jodid 200 and blood-thinning medications (anticoagulants)?

Official interaction summaries indicate that co-administration with certain blood-thinning medications (anticoagulants, e.g., Warfarin) may increase the risk of specific side effects. The simultaneous use of these medicines are often noted to require careful monitoring and potential management by a healthcare professional.

Q: Are there any known side effects from taking Jodid 200 regularly for a long period?

Although administration for deficiency prophylaxis is often long-term, regulatory information notes that prolonged use carries risks. These risks are generally linked to high iodine levels over time and include the potential for developing or exacerbating a pre-existing thyroid condition, such as latent hyperthyroidism, or experiencing iodine poisoning (iodism).

Q: Are there any specific foods that are known to interfere with the action of Jodid 200?

The official product information and regulatory guidance often contain a general caution regarding consumption. It is recommended to discuss the concurrent use of the medicine with food, alcohol, or tobacco with a healthcare professional to check for potential interactions not specifically listed.

Q: Does Jodid 200 contain lactose or gluten?

The official labeling for this product notes the presence of lactose as an excipient, which is relevant for individuals with lactose intolerance. Regulatory summaries do not typically address the presence or absence of gluten in the formulation, as its inclusion is not a major factor related to the drug's primary action.

Q: What is the research evidence that supports the use of Jodid 200 for treating iodine deficiency?

The efficacy of using supplementary iodine for deficiency prophylaxis is strongly endorsed by major public health bodies. World Health Organization (WHO) guidelines recognize iodine supplementation as a vital public health measure essential for supporting proper thyroid hormone synthesis.

Q: What does the term 'off-label use' mean in relation to a medication like Jodid 200?

The term refers to the use of a medicine for a purpose or patient group that is not specifically listed in its authorized regulatory labeling or summary of product characteristics. This classification is defined in general guidance issued by government bodies, such as the FDA or EMA.

Q: What do scientific reviews say about Jodid 200's effectiveness in radiation emergencies?

Government guidance and policy support the use of Potassium Iodide as a thyroid blocking agent in radiation emergencies. This effectiveness is achieved by saturating the thyroid gland with stable iodide, which significantly reduces the potential uptake of hazardous radioactive iodine.

Q: How does the active component of Jodid 200 compare to the active ingredients in other thyroid medicines?

Jodid 200 provides the iodide ion ( I^-) as the necessary raw material (substrate) for the thyroid gland to internally manufacture its hormones. This mechanism differs from that of other common thyroid medicines, such as Levothyroxine, which are synthetic versions of the finished thyroid hormones ( T4).

How should Jodid 200 be stored and disposed of?

Storage and Disposal of Jodid 200

The storage of Jodid 200 tablets must adhere to specific regulatory requirements to maintain the stability of Potassium Iodide. The medicine must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), and should be kept away from heat and freezing conditions.

Protection and Packaging

The tablets must be protected from light and moisture and should remain in the tightly closed, original container to prevent degradation. As a mandatory safety requirement, Jodid 200 must be kept out of the sight and reach of children at all times.

Disposal Guidelines

Expired or unused Jodid 200 must be disposed of according to local pharmaceutical waste regulations. The product should preferably be returned through a drug take-back program. Disposal must not be conducted via wastewater (sinks or toilets) to prevent environmental contamination.

Jodid 200